• A
  • A
Font Size
What is Wet AMD?

Wet AMD is a serious eye condition that can get worse. Wet AMD affects your macula (the part of the retina responsible for sharp central vision). Abnormal blood vessels grow under the macula while also leaking blood and fluid. This can damage and scar the macula.

Many people have Wet AMD. It is the leading cause of vision loss among people 50 years of age and older in the United States.

Wet AMD may cause blurriness in the center of your vision, straight lines to look wavy, and colors to look dull and washed out. It also can cause blind spots or patches or cause objects to seem farther away than they really are. These symptoms may affect your ability to read, write, drive, and recognize faces.

EYLEA is a prescription medicine approved by the Food and Drug Administration for the treatment of Wet AMD, as well as Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) in Patients with DME, and Macular Edema following Retinal Vein Occlusion (RVO). You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.

Your eye doctor will diagnose you with a retina condition that may be treated with EYLEA. A retina specialist is an ophthalmologist specially trained to diagnose and treat retina conditions such as Wet AMD.

EYLEA works by blocking vascular endothelial growth factor (VEGF), a protein made by the blood vessels. At high levels, VEGF can cause abnormal blood vessels to grow in the eye and leak fluid (the part of the retina responsible for sharp central vision). Blocking VEGF helps reduce the fluid leaking into the macula.

There is no cure for Wet AMD. Treatment with EYLEA, however, has been shown to help maintain or improve vision in many people with Wet AMD in 2 clinical trials.

The most common side effects reported in people receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.

Anyone who has an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept, should not use EYLEA.

Your eye doctor will examine, wash, and numb your eye and then administer EYLEA as an injection into the eye. Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA. Talk to your eye doctor if you experience any side effects, including eye pain, redness of the eye, light sensitivity, or blurring of vision.

It is important not to miss a scheduled injection of EYLEA. If you do, be sure to make a new appointment as soon as possible.

Each person responds to treatment with EYLEA differently, including any effects of treatment. Talk with your eye doctor about your individual response and expectations over time—he or she will monitor your progress at every step of your treatment plan.

EYLEA4U® is a support program that may be able to help. Either you or your eye doctor's office can call 1-855-EYLEA4U (1-855-395-3248) Monday through Friday 9 AM to 8 PM Eastern Time to get you started.

When your eye doctor prescribes EYLEA, whether you have private or government insurance (Medicare/Medicaid) or have no insurance coverage, you can be confident that EYLEA4U is here to help. And we can conduct a Benefits Investigation with your insurer to determine your coverage for EYLEA.

Important Safety Information
  • EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
Top
Important Safety Information
  • EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
  • Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
  • In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
  • There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
  • Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
  • The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.
  • It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.
  • EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indications

EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with:

  • Wet Age-related Macular Degeneration (AMD): The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 3 initial monthly (every 4 weeks) injections. EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need monthly (every 4 weeks) dosing after the first 3 months (12 weeks).
  • Macular Edema following Retinal Vein Occlusion (RVO): The recommended dose for EYLEA is 2 mg administered by injection in the eye monthly (every 4 weeks).
  • Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) in patients with DME: The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 5 initial monthly (every 4 weeks) injections. EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need monthly (every 4 weeks) dosing after the first 5 months (20 weeks).
Please see the full Prescribing Information for EYLEA.

The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.